• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Tulisokibart effectively induces clinical remission in moderately to severely active ulcerative colitis

byAnna YangandKiera Liblik
October 3, 2024
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed against TL1A, more effectively induced clinical remission compared with placebo.

2. Compared with placebo, the tulisokibart group consistently showed benefits in clinical response, endoscopic improvement, histologic improvement, symptomatic remission, and inflammatory biomarkers.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ulcerative colitis is a chronic, inflammatory gastrointestinal disorder characterized by abdominal cramping, diarrhea, and rectal bleeding. While current therapy for moderately to severely active ulcerative colitis includes biologic and small-molecule therapies, no existing agents are associated with a high incidence of clinical remission among patients for whom conventional therapy has been ineffective. The present trial assessed the efficacy and safety of tulisokibart compared with placebo among patients with moderately to severely active ulcerative colitis. Compared with placebo, tulisokibart was more effective for induction of clinical remission, as well as clinical response, endoscopic improvement, histologic improvement, symptomatic remission, and reduction of biomarkers of inflammatory activity. Additionally, the safety and side-effect profile of tulisokibart were similar to those of placebo. A key limitation of the study was its inability to evaluate the therapeutic index of tulisokibart, with an assessment of more significant numbers of patients over more extended periods necessary for more precise efficacy and safety evaluations. Nevertheless, these findings provide valuable insights regarding a novel treatment option for patients with ulcerative colitis who have high baseline disease activity and are often refractory to treatment.

Click to read the study in the NEJM (New England Journal of Medicine)

In-Depth [randomized controlled trial]: This phase 2 randomized-controlled trial compared the effects of tulisokibart with those of placebo on induction of clinical remission, clinical response, endoscopic improvement, histologic improvement, symptomatic remission, and levels of biomarkers of inflammatory activity. Patients 18 years of age or older with a diagnosis of moderately to severely active ulcerative colitis extending at least 15 cm from the anal verge were included. The primary outcome was clinical remission at week 12, defined as a modified Mayo endoscopic subscore of 0 or 1, a rectal-bleeding subscore of 0, and a stool-frequency subscore of 0 or 1. Out of 198 patients who underwent screening, 68 were assigned randomly to receive tulisokibart and 67 to receive a placebo. At week 12, the percentage of patients who achieved clinical remission in the tulisokibart group was 26% compared to 1% in the placebo group (95% Confidence Interval [CI], 14 to 37). Treatment differences for tulisokibart compared with placebo were 44 percentage points for achievement of clinical response (95% CI, 27 to 57), 31 percentage points for endoscopic improvement (95% CI, 17 to 43), 29 percentage points for histologic improvement (95% CI, 12 to 43), and 13 percentage points for symptomatic remission (95% CI, 2 to 25). Levels of biomarkers of inflammatory activity were also found to decrease more with tulisokibart than with placebo, with differences evident as early as week two for high-sensitivity C-reactive protein and week six for fecal calprotectin. The safety of tulisokibart was also assessed, and the safety and side-effect profile of tulisokibart was similar to those of placebo. In summary, among patients with moderately to severely active ulcerative colitis, tulisokibart was safe and more effective for induction of clinical remission.

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

Weight loss is associated with improved vascular function in patients with metabolic dysfunction-associated steatotic liver disease

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseaseGastroenterologyinternal medicineTulisokibartUlcerative Colitis
Previous Post

Mild traumatic brain injury associated with detectably neuroimaging changes and depressive symptoms

Next Post

Digital cognitive therapy program may be effective for alcohol use disorder

RelatedReports

A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
Fatty liver disease may independently predict high-risk coronary disease
Cardiology

Weight loss is associated with improved vascular function in patients with metabolic dysfunction-associated steatotic liver disease

August 21, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

June 29, 2026
Sugary drinks and liver cancer collage: an engraved liver beside a glass of dark fizzy drink with ice and rising bubbles
All Specialties

High intake of sugar-sweetened beverages is associated with increased risk of hepatocellular carcinoma

June 19, 2026
Next Post
Patient communication collage: two empty armchairs facing each other, a side table with two cups and a floor lamp

Digital cognitive therapy program may be effective for alcohol use disorder

#VisualAbstrcat: Lamotrigine and Mexiletine Treatments Resulted in Similar Improvements for Non-Dystrophic Myotonias

#VisualAbstrcat: Lamotrigine and Mexiletine Treatments Resulted in Similar Improvements for Non-Dystrophic Myotonias

Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography

Neuroprosthesis enables conversational communication in amyotrophic lateral sclerosis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder
  • In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity
  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.